Metrics as of 10/16/2026, 10:41 AM (Berlin time), refresh in progress.
Elutia Stock
Elutia Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- C. Randal Mills
- Employees
- 26
- Market cap
- $35 M
- IPO
- 07/10/2020
- Web
- elutia.com
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic…
Elutia stock: price history
1D
+0.7%
1W
-3.5%
1M
-2.0%
6M
-31.0%
YTD
+14.6%
1Y
-11.8%
2Y
-79.2%
5Y
-85.4%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~111% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Elutia
Analyst assessment of Elutia
PRICE TARGET LOW
US$5.00
CONSENSUS
US$8.88
MEDIAN
US$10.00
PRICE TARGET HIGH
US$10.50
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 10/09/2025
Elutia stock metrics
P/E
0.61
P/B
2.2
EV/EBITDA
-1.08
RETURN ON EQUITY
-48.6%
NET MARGIN
-315.0%
DEBT/EQUITY
0.69
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
79.8%
FLOAT SHARES
35,347,343
AVG. DAILY VOLUME (30D)
315,575
Insider transactions (SEC)
Ferguson Matthew
Ferguson Matthew
Williams Michelle LeRoux
Williams Michelle LeRoux
Mills C Randal
Comparable stocks
Frequently asked questions about Elutia stock
What does Elutia do?
Elutia Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is C. Randal Mills, the company employs around 26 people.
The IPO was on 07/10/2020; the stock trades on NASDAQ under the ticker ELUT.
What do analysts say about Elutia stock?
5 analysts rate the stock, the consensus is Buy (as of 10/09/2025).
The average price target is US$8.88, ranging from US$5.00 to US$10.50, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does Elutia report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 111% stronger than usual.
Does Elutia pay a dividend?
No, Elutia currently does not pay a dividend.
Which stocks are comparable to Elutia?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Elutia stock analyzed?
Clicking "Analyze stock" lets five strategies assess Elutia against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.